Stockscreener 앱 받기
6.76
0.00%
0.00
전일 마감가:
$6.76
열려 있는:
$6.56
하루 거래량:
462.70K
Relative Volume:
1.48
시가총액:
$269.02M
수익:
$68.68M
순이익/손실:
$-60.84M
주가수익비율:
-4.225
EPS:
-1.6
순현금흐름:
$-38.42M
1주 성능:
-0.88%
1개월 성능:
-22.03%
6개월 성능:
-7.40%
1년 성능:
-13.99%
1일 변동 폭
$6.42
$6.86
1주일 범위
$6.40
$7.06
52주 변동 폭
$5.46
$10.01
풀몬스 Stock (LUNG) Company Profile
명칭
Pulmonx Corp
전화
650-364-0400
주소
700 CHESAPEAKE DRIVE, REDWOOD CITY
LUNG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LUNG
Pulmonx Corp
|
6.76 | 269.02M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
124.44 | 215.82B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
345.80 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
89.70 | 132.67B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
82.88 | 106.28B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.36 | 40.63B | 5.72B | 4.17B | 259.90M | 6.97 |
풀몬스 Stock (LUNG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-10 | 개시 | D. Boral Capital | Buy |
| 2024-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-06-04 | 개시 | Lake Street | Buy |
| 2024-02-23 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | 개시 | Craig Hallum | Buy |
| 2023-02-27 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-07-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-02 | 재개 | BofA Securities | Neutral |
| 2021-12-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | 개시 | Citigroup | Buy |
| 2021-03-25 | 개시 | Piper Sandler | Neutral |
| 2021-03-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-10-26 | 개시 | BofA Securities | Buy |
| 2020-10-26 | 개시 | Canaccord Genuity | Buy |
| 2020-10-26 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-10-26 | 개시 | Stifel | Buy |
| 2020-10-26 | 개시 | Wells Fargo | Equal Weight |
모두보기
풀몬스 주식(LUNG)의 최신 뉴스
Charles Schwab Investment Management Inc. Boosts Holdings in Pulmonx Co. (NASDAQ:LUNG) - Defense World
Pulmonx Co. (NASDAQ:LUNG) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Connor Clark & Lunn Investment Management Ltd. Buys 25,988 Shares of Pulmonx Co. (NASDAQ:LUNG) - Defense World
Insider Sell Alert: French Glendon E. III Sells 20,000 Shares of Pulmonx Corp (LUNG) - GuruFocus
Pulmonx corp director Glendon French sells $157,000 in stock By Investing.com - Investing.com Canada
Pulmonx corp director Glendon French sells $157,000 in stock - Investing.com
Canaccord maintains Buy rating on Pulmonx stock with $16 target By Investing.com - Investing.com Australia
Canaccord maintains Buy rating on Pulmonx stock with $16 target - Investing.com
Boral Capital sets Pulmonx stock Buy rating, $17 target - Investing.com India
Boral Capital sets Pulmonx stock Buy rating, $17 target By Investing.com - Investing.com South Africa
This Pulmonx Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Pulmonx initiated with a Buy at D. Boral Capital - TipRanks
Pulmonx (NASDAQ:LUNG) vs. Spectral Medical (OTCMKTS:EDTXF) Financial Review - The AM Reporter
Reviewing Pulmonx (NASDAQ:LUNG) & Spectral Medical (OTCMKTS:EDTXF) - Defense World
Pulmonx corp’s chief commercial officer sells $41,191 in stock - Investing.com India
Pulmonx corp general counsel sells shares totaling $170,918 - Investing.com India
Pulmonx CFO Mehul Joshi sells $102,414 in stock By Investing.com - Investing.com Australia
Pulmonx Corp CEO Steven Williamson sells $197,699 in stock - Investing.com India
Pulmonx CFO Mehul Joshi sells $102,414 in stock - Investing.com India
Pulmonx corp’s chief commercial officer sells $41,191 in stock By Investing.com - Investing.com South Africa
Can This Medical Device Expert Help EDAP Dominate the $8.5B Prostate Cancer Market? - StockTitan
Pulmonx Co. (NASDAQ:LUNG) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Pulmonx director French Glendon E. III sells shares worth $29,625 - MSN
Pulmonx director French Glendon E. III sells $459,085 in shares By Investing.com - Investing.com Canada
Pulmonx director French Glendon E. III sells $459,085 in shares - Investing.com India
Pulmonx Corporation shares spike on record-breaking Q4 revenue - Mugglehead
Stock summary: Pulmonx witnessed weekly surge of 20.43% after fourth-quarter earnings exceed expectations - Business Upturn
Top 3 Health Care Stocks You May Want To Dump In February - Benzinga
Pulmonx Corporation (NASDAQ:LUNG) Q4 2024 Earnings Call Transcript - Insider Monkey
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - MSN
Citi raises Pulmonx stock target following record revenue - Investing.com India
Citi raises Pulmonx stock target following record revenue By Investing.com - Investing.com Nigeria
Pulmonx Corp (LUNG) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Financial ... - Yahoo Finance
Pulmonx earnings beat by $0.12, revenue topped estimates - Investing.com
Earnings call transcript: Pulmonx Q4 2024 earnings beat expectations, stock jumps - Investing.com India
Can Pulmonx's 22% Revenue Surge and Treatment Center Expansion Transform Severe COPD Care? - StockTitan
What To Expect From Pulmonx Corp (LUNG) Q4 2024 Earnings - Yahoo Finance
Pulmonx (LUNG) Expected to Announce Quarterly Earnings on Wednesday - Armenian Reporter
Exclusive: Pulmonx Reveals Future Roadmap at Major Healthcare Investor Summit - StockTitan
Pulmonx Co. (NASDAQ:LUNG) Stake Lifted by SG Americas Securities LLC - Defense World
Pulmonx (LUNG) Projected to Post Quarterly Earnings on Wednesday - Defense World
Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Pulmonx Co. (NASDAQ:LUNG) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Pulmonx Earnings Watch: Key Q4 Financial Results Coming February 19Mark Your Calendar - Stock Titan
Morgan Stanley Reduces Stake in Pulmonx Corp by 21.74% - GuruFocus.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
풀몬스 (LUNG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.46%
자본화:
|
볼륨(24시간):